Full Text View
Tabular View
Study Results
Related Studies
Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg
This study has been completed.
Study NCT01256086   Information provided by MEDA Pharma GmbH & Co. KG

First Received on December 7, 2010.   Last Updated on August 13, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Asthma
More general conditions related to this trial
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Interventions listed in this trial
Formatris 24µg
Formatris 12µg
Foradil P 24µg
Foradil P 12µg
Additional drug interventions recognized in this trial
Formoterol
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses
Sponsors listed in this trial
MEDA Pharma GmbH & Co. KG
ClinResearch GmbH, Cologne, Germany
Trio Clinical Research, LLC, Raleigh, USA
NuCara Pharmacy, Waterloo, USA
Prof. Hochhaus, Gainesville, USA


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services